NASDAQ:PLSE Pulse Biosciences - PLSE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pulse Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.08 +0.09 (+3.01%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.98▼$3.1350-Day Range$2.52▼$3.8852-Week Range$1.18▼$5.46Volume37,690 shsAverage Volume51,500 shsMarket Capitalization$114.67 millionP/E RatioN/ADividend YieldN/APrice Target$11.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Pulse Biosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside262.6% Upside$11.17 Price TargetShort InterestBearish12.80% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector686th out of 983 stocksSurgical & Medical Instruments Industry64th out of 100 stocks 3.0 Analyst's Opinion Consensus RatingPulse Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.17, Pulse Biosciences has a forecasted upside of 262.6% from its current price of $3.08.Amount of Analyst CoveragePulse Biosciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.80% of the float of Pulse Biosciences has been sold short.Short Interest Ratio / Days to CoverPulse Biosciences has a short interest ratio ("days to cover") of 26.5, which indicates bearish sentiment.Change versus previous monthShort interest in Pulse Biosciences has recently decreased by 5.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulse Biosciences does not currently pay a dividend.Dividend GrowthPulse Biosciences does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePulse Biosciences has received a 61.90% net impact score from Upright. Pulse Biosciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Taxes". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Diagnostic and treatment machines", "Medical devices engineering", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Pulse Biosciences is -0.60. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulse Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders55.00% of the stock of Pulse Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.56% of the stock of Pulse Biosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulse Biosciences is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulse Biosciences is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulse Biosciences has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pulse Biosciences (NASDAQ:PLSE) StockPulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.Read More Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PLSE Stock News HeadlinesMarch 10, 2023 | finance.yahoo.comEven after rising 18% this past week, Pulse Biosciences (NASDAQ:PLSE) shareholders are still down 79% over the past five yearsMarch 3, 2023 | finance.yahoo.comPulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023March 21, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 2, 2023 | finance.yahoo.comPulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF SymposiumJanuary 5, 2023 | marketwatch.comBellerophon Therapeutics Shares Double After INOpulse License DealDecember 10, 2022 | finance.yahoo.comPulse Biosciences, Inc. (NASDAQ:PLSE) insiders have recently purchased stock and their bets paid off last week as company hit US$108m market capNovember 10, 2022 | finance.yahoo.comPulse Biosciences Reports Third Quarter 2022 Financial ResultsNovember 9, 2022 | msn.comEarnings Preview: Pulse BiosciencesMarch 21, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. October 27, 2022 | finance.yahoo.comPulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022October 14, 2022 | finance.yahoo.comInsider Buying: The Pulse Biosciences, Inc. (NASDAQ:PLSE) Chief Strategy Officer & Director Just Bought 70% More SharesOctober 12, 2022 | nasdaq.comWednesday 10/12 Insider Buying Report: PLSE, RGPOctober 6, 2022 | nasdaq.comEven after rising 48% this past week, Pulse Biosciences (NASDAQ:PLSE) shareholders are still down 87% over the past yearOctober 6, 2022 | finance.yahoo.comPulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma LesionsOctober 1, 2022 | finance.yahoo.comPulse Biosciences (NASDAQ:PLSE) adds US$29m to market cap in the past 7 days, though investors from a year ago are still down 89%September 28, 2022 | seekingalpha.comPulse Biosciences wins FDA clearance to expand use of CellFX SystemSeptember 26, 2022 | marketwatch.comPulse Biosciences Wins Expanded FDA Clearance for CellFX SystemSeptember 26, 2022 | nasdaq.comPulse Biosciences Receives FDA Clearance For The Treatment Sebaceous HyperplasiaSeptember 26, 2022 | finance.yahoo.comPulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous HyperplasiaSeptember 21, 2022 | marketwatch.comPulse Biosciences Shares Up 15% After Shift in Strategic Focus, Leadership ChangesSeptember 21, 2022 | finance.yahoo.comPulse Biosciences Shifts Core Technology Focus, Reduces Dermatologic FootprintSeptember 20, 2022 | marketwatch.comPulse Biosciences Shares Up 15% After-Hours on Leadership Shuffle, Shift in Strategic FocusSeptember 20, 2022 | finance.yahoo.comPulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse StimulationSeptember 11, 2022 | finance.yahoo.comPulse Biosciences, Inc. (PLSE)August 10, 2022 | msn.comRecap: Pulse Biosciences Q2 EarningsAugust 10, 2022 | seekingalpha.comPulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2022 Results - Earnings Call TranscriptAugust 10, 2022 | finance.yahoo.comPulse Biosciences Reports Second Quarter 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PLSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PLSE Company Calendar Last Earnings11/15/2021Today3/21/2023Next Earnings (Confirmed)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLSE CUSIPN/A CIK1625101 Webwww.pulsebiosciences.com Phone(510) 906-4600FaxN/AEmployees142Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.17 High Stock Price Forecast$13.00 Low Stock Price Forecast$8.50 Forecasted Upside/Downside+262.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,660,000.00 Net Margins-2,866.34% Pretax Margin-4,167.67% Return on Equity-290.24% Return on Assets-112.58% Debt Debt-to-Equity Ratio10.50 Current Ratio10.17 Quick Ratio10.06 Sales & Book Value Annual Sales$1.42 million Price / Sales80.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book2.57Miscellaneous Outstanding Shares37,230,000Free Float16,753,000Market Cap$114.67 million OptionableOptionable Beta1.11 Key ExecutivesKevin DanahyPresident & Chief Executive OfficerEdison ManuelVice President-OperationsDarrin R. UeckerChief Technology OfficerDavid DanitzSenior Vice President-EngineeringRichard NuccitelliChief Science OfficerKey CompetitorsBioventusNYSE:BVSAkiliNASDAQ:AKLIDarioHealthNASDAQ:DRIOHealth Sciences Acquisitions Co. 2NASDAQ:HSAQOrchestra BioMedNASDAQ:OBIOView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 13,606 shares on 2/15/2023Ownership: 0.121%State of Wisconsin Investment BoardSold 25,100 shares on 2/15/2023Ownership: 0.106%Susquehanna International Group LLPBought 86,700 shares on 2/14/2023Ownership: 0.000%Geode Capital Management LLCBought 6,388 shares on 2/13/2023Ownership: 0.375%Advisor Group Holdings Inc.Bought 18,079 shares on 2/10/2023Ownership: 0.181%View All Insider TransactionsView All Institutional Transactions PLSE Stock - Frequently Asked Questions Should I buy or sell Pulse Biosciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PLSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares. View PLSE analyst ratings or view top-rated stocks. What is Pulse Biosciences' stock price forecast for 2023? 3 brokerages have issued 12 month target prices for Pulse Biosciences' shares. Their PLSE share price forecasts range from $8.50 to $13.00. On average, they predict the company's share price to reach $11.17 in the next year. This suggests a possible upside of 262.6% from the stock's current price. View analysts price targets for PLSE or view top-rated stocks among Wall Street analysts. How have PLSE shares performed in 2023? Pulse Biosciences' stock was trading at $2.77 on January 1st, 2023. Since then, PLSE stock has increased by 11.2% and is now trading at $3.08. View the best growth stocks for 2023 here. When is Pulse Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our PLSE earnings forecast. How can I listen to Pulse Biosciences' earnings call? Pulse Biosciences will be holding an earnings conference call on Thursday, March 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Pulse Biosciences' earnings last quarter? Pulse Biosciences, Inc. (NASDAQ:PLSE) announced its earnings results on Monday, November, 15th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.05. The company had revenue of $0.57 million for the quarter. Pulse Biosciences had a negative net margin of 2,866.34% and a negative trailing twelve-month return on equity of 290.24%. During the same period last year, the firm posted ($0.51) earnings per share. What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO? 2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pulse Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX). When did Pulse Biosciences IPO? (PLSE) raised $20 million in an initial public offering on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO. What is Pulse Biosciences' stock symbol? Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE." Who are Pulse Biosciences' major shareholders? Pulse Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (0.47%), Geode Capital Management LLC (0.37%), Westside Investment Management Inc. (0.37%), Susquehanna International Group LLP (0.00%), Advisor Group Holdings Inc. (0.18%) and Millennium Management LLC (0.12%). Insiders that own company stock include Kevin Patrick Danahy, Maky Zanganeh and Mitchell E Levinson. View institutional ownership trends. How do I buy shares of Pulse Biosciences? Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pulse Biosciences' stock price today? One share of PLSE stock can currently be purchased for approximately $3.08. How much money does Pulse Biosciences make? Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $114.67 million and generates $1.42 million in revenue each year. The company earns $-63,660,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. How many employees does Pulse Biosciences have? The company employs 142 workers across the globe. How can I contact Pulse Biosciences? Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for the company is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com. This page (NASDAQ:PLSE) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.